|
|
|
|
PUBLICATIONS FOCUSING ON UROLOGIC CANCER TREATMENTS THROUGH ORIGINAL MANUSCRIPTS
|
|
|
|
Prostate Cancer and Prostatic Diseases |
Performance of PCA3 and TMPRSS2: ERG Urinary Biomarkers in Prediction of Biopsy Outcome in the Canary Prostate Active Surveillance Study (PASS)
|
Full Text Article
|
For men on active surveillance for prostate cancer, biomarkers may improve the prediction of reclassification to a higher grade or volume cancer. This study examined the association of urinary Prostate Cancer Gene 3 (PCA3) and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification.
|
|
|
|
|
The Association of Urinary PCA3 and TMPRSS2:ERG with Biopsy-based Reclassification
|
Commentary by Jack Schalken, Ph.D
|
The dilemma that resulted from the widespread use of serum prostate-specific androgen (PSA) testing was the identification of a significant number of men with indolent pure red cell aplasia (PrCa). After a significant period of overtreatment, the implementation of active surveillance (AS) has partly solved that issue. However, 25-50 % of AS patients will undergo an intervention. The follow up is rather invasive including serum PSA and repeat biopsies.
|
|
|
|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
|
|
Real-World Evaluation of Disparities in Prostate Cancer Outcomes
|
Daniel Spratt, MD
|
Daniel Spratt and Todd Morgan discuss the analysis of why is it that African American men appear to be dying more often of prostate cancer. They review their approach to understanding more about this real-world question.
|
|
|
|
|
|
|
|
|
|
Disparities in Prostate Cancer Clinical Trial Participation
|
Hala Borno, MD
|
Hala Borno and Charles Ryan discuss the ongoing and increasing problems in the enrollment of clinical trials in oncology. Hala describes her goals in this area and her passion for uncovering differences that lead to inequities.
|
|
|
|
|
|
|
|
|
|
Disparities in Prostate Cancer Management in the United States
|
Alicia Morgans, MD, MPH
|
Alicia Morgans presented on disparities in prostate cancer management in the United States. Dr. Morgans highlights the 174,650 new cases of prostate cancer in the United States in 2019 and noting that social health is determined by many factors which could be responsible for these disparities.
|
|
|
|
|
|
|
|
|
Increasing Rates of Active Surveillance as the Standard of Care in Men with Low-Risk Prostate Cancer
|
Matthew Cooperberg, MD, MPH, FACS
Matt Cooperberg discusses active surveillance as the standard of care for men with low-risk prostate cancer. He reviews data from multiple registries including CaPSURE, MUSIC, AQUA, and SEER, which report increasing rates of active surveillance in men with low-risk disease.
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES
|
|
|
|
|
African American Race is Not Associated with Reclassification During Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study
|
Lisa Newcomb, PhD
|
Lisa Newcomb and colleagues presented their results of African American patients on active surveillance as part of the Canary Prostate Cancer Active Surveillance Study (PASS). The objective of this study was to evaluate whether race is associated with risk of reclassification in a well-established prospective active surveillance cohort that utilizes protocol-driven PSA measurements and surveillance biopsies.
|
|
|
|
|
|
|
|
Anything but Black and White - Racial Disparities in Prostate Cancer
|
Daniel J. George, MD
|
Race is a complex topic in any setting, but in healthcare, it is particularly challenging given the influence of social, lifestyle, and structural determinants associated with racial populations. Make no mistake, race matters in cancer outcomes; in prostate cancer, in particular, year after year black men consistently die at nearly 2.5 times the rate of white men with the same disease.
|
|
|
|
|
|
|
Disparities in Prostate Cancer Management in the United States
|
Alicia Morgans, MD, MPH
|
Alicia Morgans presented on disparities in prostate cancer management in the United States. She began her presentation stating that social health is determined by many factors which could be responsible for these disparities. There were 174650 new cases of prostate cancer in the US in 2019. Black Americans have approximately 2 times higher incidence of prostate cancer vs. white Americans, and ~2.5 times higher mortality.
|
|
|
|
|
Plenary DEBATE: Where’s the Evidence Residual Fragments: Active Intervention vs Surveillance
|
Kenneth Pace, MD, MSc, FRCSC
|
Kenneth Pace began his argument in favor of active surveillance of calcium oxalate fragments with an overview of residual stone fragment detection. Dr. Pace stated that we should be calling any fragments “clinically insignificant” because in reality, even small, fragments can cause stone-related events. From Dr. Pearle’s 1999 study, CT scan is the gold standard of fragment detection, although it can overcall fragment size and a 12% false positive rate.
|
|
|
|
|
From Trials to Treatment: Addressing Disparities in Access to Prostate Cancer Care
|
Hala Borno, MD, BS
|
Hala Borno, MD, BS, presented on the disparities in access to prostate cancer care in the United States. The incidence of prostate cancer in the US has been decreasing over time and the treatment paradigm in this era of precision medicine has changed significantly, in each disease stage of prostate cancer, with the use of genomics, molecular imaging and clinical trials.
|
|
|
|
|
|
|
|
|
Abstract Commentaries |
Assessing the Relationship between Statin Use and Oncologic Outcomes Among Men Electing Active Surveillance for Localized Prostate Cancer
|
Lamont J. Wilkins, and Yaw A. Nyame, MD, MBA
|
There has been an increase in the use of active surveillance (AS) over the last 5-10 years. However, the rate of treatment among men electing AS is approximately 50% at 10-years. This raises the question: is there an intervention that can delay disease progression and/or prevent the need for intervention? One potential therapeutic agent that could be considered are HMG-CoA reductase inhibitors—also known as statins.
|
|
|
|
|
Influence of Physical Activity on Active Surveillance Discontinuation in Men with Low-Risk Prostate Cancer
|
Efthymios Papadopoulos, Shabbir M.H. Alibhai, and Daniel Santa Mina
|
In this abstract commentary, Efthymios Papadopoulos and colleagues provided a discussion on the recently published article in Cancer Causes & Control on the influence of physical activity on active surveillance (AS) discontinuation in men with low-risk prostate cancer. AS offers men with indolent, organ-confined disease the option to defer curative treatment and its associated adverse effects that pose a significant threat to quality of life.
|
|
|
|
|
|